loading...| Preferred Name |
Tositumomab |
|
| Synonyms |
|
|
| Definitions |
A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells. Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C2543 |
|
| Accepted_Therapeutic_Use_For |
CD20 Positive Follicular Non-Hodgkins Lymphoma Refractory to Rituximab |
|
| ALT_DEFINITION |
A monoclonal antibody that is used in the treatment of certain types of non-Hodgkin lymphoma. When tositumomab and iodine I 131 tositumomab (a form of tositumomab that has been chemically changed by adding radioactive iodine) are given together, the combination is called the Bexxar regimen. |
|
| CAS_Registry |
192391-48-3 |
|
| code |
C2543 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A murine IgG2 monoclonal antibody directed against the CD20 antigen, found on the surface of B-cells. Tositumomab binds to the CD20 surface membrane antigen, resulting in apoptosis, and may stimulate antitumoral cell-mediated and/or antibody-dependent cytotoxicity. (NCI04) |
|
| Display_Name |
Tositumomab |
|
| FDA_UNII_Code |
0343IGH41U |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Tositumomab |
|
| Legacy Concept Name |
Tositumomab |
|
| Maps_To |
Tositumomab |
|
| NCI_Drug_Dictionary_ID |
37818 |
|
| PDQ_Closed_Trial_Search_ID |
37818 |
|
| PDQ_Open_Trial_Search_ID |
37818 |
|
| Preferred_Name |
Tositumomab |
|
| prefixIRI |
NCIT:C2543 |
|
| prefLabel |
Tositumomab |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| UMLS_CUI |
C0879399 |
|
| subClassOf |